Independent industry coverage
FDA • MedTech • Biotechnology • Healthcare Business

Medical Device News & MedTech Industry Updates

lead story

Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical

GV101, is a novel, highly selective ROCK2 inhibitor, yielded an 86.2% best overall response rate (bORR) at 400 mg and a 67.9% bORR at 200 mg at 24 weeks in chronic Graft versus Host Disease (cGvHD) patients who had failed at least two prior lines of therapy

Read More »

Healthcare Careers | Nurses Corner

Health and Lifestyle

Articles of Interest

For industry partners

Reach the medical technology community

Connect your brand with healthcare leaders, medical specialists, and industry decision-makers.